{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:57:52Z","timestamp":1790758672657,"version":"4.1.0"},"reference-count":102,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["DRO \u2010 FNOs\/2016\/21 and (17\u201030089A)"],"award-info":[{"award-number":["DRO \u2010 FNOs\/2016\/21 and (17\u201030089A)"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006704","name":"Ostravsk\u00e1 Univerzita v Ostrav\u011b","doi-asserted-by":"publisher","award":["IRP201550"],"award-info":[{"award-number":["IRP201550"]}],"id":[{"id":"10.13039\/501100006704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunology"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The introduction of PD\u20101\/PD\u2010L1 pathway inhibitors is an important landmark in solid oncology with unprecedented practice\u2010changing activity in various types of solid tumours. Among haematological malignancies, <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u20101\/<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u2010L1 inhibitors have been successful, so far, only in the treatment of classical Hodgkin lymphoma, which typically exhibits an over\u2010expression of <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u20101 ligands (<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u2010L1, <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u2010L2) due to alterations in chromosome 9p24.1. Such positive outcomes led to the US Food and Drug Administration approval of nivolumab use in relapsed Hodgkin lymphoma in 2016 as the first haematological indication. Although the results in other lymphoid malignancies have not been so striking, blockade of the <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u20101\/<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u2010L1 axis has led to meaningful responses in other lymphoma types such as diffuse large B\u2010cell lymphoma, follicular lymphoma or several T\u2010cell lymphomas. Monotherapy with <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u20101\/<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u2010L1 inhibitors in chronic lymphocytic leukaemia and multiple myeloma has been unsatisfactory, suggesting that a combinational approach with other synergistic drugs is needed. In the case of multiple myeloma, immunomodulatory agents together with corticosteroids represent the most promising combinations. Among myeloid malignancies, the anti\u2010<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u20101 monoclonal antibodies are examined dominantly in acute myeloid leukaemia and myelodysplastic syndromes in combination with potentially synergistic hypomethylating drugs such as 5\u2010azacitidine, resulting in promising outcomes that warrant further investigation. We have described all available clinical results of <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u20101\/<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\u2010L1 inhibitors in haematological malignancies and discussed related toxicities, as well as highlighted crucial preclinical studies in this review.<\/jats:p>","DOI":"10.1111\/imm.12788","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T11:53:09Z","timestamp":1499428389000},"page":"357-371","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["<scp>PD<\/scp>\u20101\/<scp>PD<\/scp>\u2010L1 inhibitors in haematological malignancies: update 2017"],"prefix":"10.1111","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-9253","authenticated-orcid":false,"given":"Tomas","family":"Jelinek","sequence":"first","affiliation":[{"name":"Department of Haemato\u2010oncology University Hospital Ostrava Ostrava Czech Republic"},{"name":"Faculty of Medicine University of Ostrava Ostrava Czech Republic"},{"name":"Faculty of Science University of Ostrava Ostrava Czech Republic"},{"name":"Centro de Investigacion Medica Aplicada (CIMA) Clinica Universidad de Navarra IDISNA Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Mihalyova","sequence":"additional","affiliation":[{"name":"Department of Haemato\u2010oncology University Hospital Ostrava Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kascak","sequence":"additional","affiliation":[{"name":"Department of Haemato\u2010oncology University Hospital Ostrava Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juraj","family":"Duras","sequence":"additional","affiliation":[{"name":"Department of Haemato\u2010oncology University Hospital Ostrava Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[{"name":"Department of Haemato\u2010oncology University Hospital Ostrava Ostrava Czech Republic"},{"name":"Faculty of Medicine University of Ostrava Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1961"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1337"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.017"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0551-1"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1213633"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481302000108"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.08.004"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00922.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.005"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1254856"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324270"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.11.7372"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324228"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.05.005"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02844-06"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03402041"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.776"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.03.005"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.03.025"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-085159"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1110.1110"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/blood.V126.23.3979.3979","article-title":"Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin's lymphoma after allogeneic hematopoietic cell transplantation: a study from the lysa and SFGM\u2010TC","volume":"126","author":"Herbaux C","year":"2015","journal-title":"Blood"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.11.916"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood.V128.22.1105.1105","article-title":"Preliminary results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Herrera AF","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1106.1106"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.183.183"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V128.22.1107.1107","article-title":"Pembrolizumab in relapsed\/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 keynote\u2010087 study","volume":"128","author":"Moskowitz CH","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood.V128.22.2999.2999","article-title":"PD\u20101 blockade after epigenetic therapy in patients with relapsed or refractory Hodgkin lymphoma: higher\u2010than\u2010expected rate of complete responses","volume":"128","author":"Falchi L","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629600"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V128.22.619.619","article-title":"Phase 1b study of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B\u2010cell lymphoma: results from the ongoing keynote\u2010013 trial","volume":"128","author":"Zinzani PL","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3685"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12176"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-649905"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2660"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1257"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-421826"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70551-5"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2356"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-698936"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2011.03.003"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-055145"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10864"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.2089"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e31821c35cb"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.200"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.181.181"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051482"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.213"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.11"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.03.011"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202005"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.79"},{"key":"e_1_2_10_73_1","doi-asserted-by":"crossref","unstructured":"MateosM\u2010V OrlowskiRZ SiegelDSD ReeceDE MoreauP OcioEMet al. (2016)Pembrolizumab in combination with lenalidomide and low\u2010dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): Final efficacy and safety analysis. In: Journal of Clinical Oncology [Internet]. Chicago; 2016. p. J Clin Oncol 34 (suppl; abstr 8010). (english; vol. 34). URLhttp:\/\/meetinglibrary.asco.org\/content\/167184-176[accessed on 7 January 2017]","DOI":"10.1200\/JCO.2016.34.15_suppl.8010"},{"key":"e_1_2_10_74_1","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/blood.V128.22.2119.2119","article-title":"Pembrolizumab in combination with pomalidomide and dexamethasone (PEMBRO\/POM\/DEX) for pomalidomide exposed relapsed or refractory multiple myeloma","volume":"128","author":"Wilson L","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1838.1838"},{"key":"e_1_2_10_76_1","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1182\/blood.V126.23.4218.4218","article-title":"Blockade of PD\u20101 in combination with dendritic cell\/myeloma fusion cell vaccination following autologous stem cell transplantation is well tolerated, induces anti\u2010tumor immunity and may lead to eradication of measureable disease","volume":"126","author":"Rosenblatt J","year":"2015","journal-title":"Blood"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077537"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2005.09.029"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2630"},{"key":"e_1_2_10_80_1","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay AG","year":"2008","journal-title":"J Clin Invest"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622936"},{"key":"e_1_2_10_82_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V128.22.59.59","article-title":"Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial","volume":"128","author":"Jain N","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_83_1","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1182\/blood.V128.22.4392.4392","article-title":"PD\u20101 blockade with pembrolizumab in relapsed CLL including Richter's transformation: an updated report from a phase 2 trial (MC1485)","volume":"128","author":"Ding W","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4079"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2672"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0909-y"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12228"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.214"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.7.5.5689"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0108"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-206672"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3324"},{"key":"e_1_2_10_94_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.V128.22.763.763","article-title":"Phase IB\/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML)","volume":"128","author":"Daver N","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-255125"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.355"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1107554"},{"key":"e_1_2_10_98_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V128.22.344.344","article-title":"A phase II study evaluating the combination of nivolumab (Nivo) or ipilimumab (Ipi) with azacitidine in Pts with previously treated or untreated myelodysplastic syndromes (MDS)","volume":"128","author":"Garcia\u2010Manero G","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.345.345"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.16.4601"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1535"},{"key":"e_1_2_10_103_1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood.V128.22.490.490","article-title":"Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"128","author":"Badros AZ","year":"2016","journal-title":"Blood"}],"container-title":["Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimm.12788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imm.12788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T14:30:58Z","timestamp":1695997858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imm.12788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/imm.12788"],"URL":"https:\/\/doi.org\/10.1111\/imm.12788","archive":["Portico"],"relation":{},"ISSN":["0019-2805","1365-2567"],"issn-type":[{"value":"0019-2805","type":"print"},{"value":"1365-2567","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,4]]},"assertion":[{"value":"2017-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}